hGHRH(1-32)NH2 vs Anamorelin
Head-to-head comparison of hGHRH(1-32)NH2 (Human growth hormone-releasing factor (1-32) amide) and Anamorelin (Anamorelin hydrochloride (ONO-7643)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | hGHRH(1-32)NH2 | Anamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Full Name | Human growth hormone-releasing factor (1-32) amide | Anamorelin hydrochloride (ONO-7643) |
| Molecular Weight | N/A | N/A |
| Half-Life | 5-15 minutes | about 9 hours |
| Amino Acids | 32 | N/A |
| Typical Dose | 0.1-1 mcg/kg | 50 mg/day |
| Route | Subcutaneous/IV | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 50 | 95 |
| Research Status | Clinical Research | Clinical |
hGHRH(1-32)NH2 Benefits
- ✓GH pulse induction
- ✓core-sequence testing
- ✓receptor signaling studies
- ✓protease-resistance comparisons
Anamorelin Benefits
- ✓stimulates appetite
- ✓raises IGF-1
- ✓may support weight gain
- ✓oral dosing
hGHRH(1-32)NH2 Dosing
0.1-1 mcg/kg SC or IV bolus|acute GH-response testing with timed blood draws|pulsatile dosing in receptor studies
Anamorelin Dosing
50 mg orally once daily|often studied with food or per protocol|track weight, appetite, and glucose markers
hGHRH(1-32)NH2 Side Effects
- ⚠headache
- ⚠flushing
- ⚠injection-site irritation
Anamorelin Side Effects
- ⚠hyperglycemia
- ⚠peripheral edema
- ⚠constipation or nausea
Research Overview
hGHRH(1-32)NH2
Human GHRF(1-32)NH2 is used in basic and translational studies to evaluate how the active N-terminal region of GHRH drives pituitary hormone release. It helps define the lower bound of sequence length needed for meaningful biological activity.
Anamorelin
Trials in cachexia populations showed increased appetite and modest gains in body weight and IGF-1. Regulatory progress has varied by region, but it remains a well-studied ghrelin agonist in the GH space.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.